-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Phoebe D. Sharkey, PhD

Articles by Phoebe D. Sharkey, PhD

Opportunities and Challenges in Medicaid Managed Care: The Experience in Maryland

ByPhoebe D. Sharkey, PhD,Frederick W. Derrick, PhD,Janet Freeze, JD,Roosevelt Bush, DDS, MPH,Sandra Gooding, PhD,John Cotner, PhD,Anthon

March 1st 2000

Continuity of Care: Is It Cost Effective?

ByMichele Raddish, MD, MPH,Susan D. Horn, PhD,Phoebe D. Sharkey, PhD

June 1st 1999

Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project

BySusan D. Horn, PhD,Phoebe D. Sharkey, PhD,Cheryl Phillips-Harris, MD

August 1st 1998

Managed Care Outcomes Project: Study Design, Baseline Patient Characteristics, and Outcome Measures

BySusan D. Horn, PhD,Phoebe D. Sharkey, PhD,Julie Gassaway, RN, MS

March 1st 1996

Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project

BySusan D. Horn, PhD,Phoebe D. Sharkey, PhD,Diane M. Tracy, PhD,Corinne E. Horn,Blair James,Frederick Goodwin, MD

March 1st 1996

Latest Updated Articles

Managed Care Outcomes Project: Study Design, Baseline Patient Characteristics, and Outcome Measures
March 1st 1996
Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project
March 1st 1996
Opportunities and Challenges in Medicaid Managed Care: The Experience in Maryland
March 1st 2000
Continuity of Care: Is It Cost Effective?
June 1st 1999
Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project
August 1st 1998

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS